Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations: 2018-2023

Historic Liabilities from Discontinued Operations for Aclaris Therapeutics (ACRS) over the last 4 years, with Dec 2023 value amounting to $2.2 million.

  • Aclaris Therapeutics' Liabilities from Discontinued Operations changed negligibly% to $2.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.2 million for FY2023, which is negligibly% changed negligibly from last year.
  • Per Aclaris Therapeutics' latest filing, its Liabilities from Discontinued Operations stood at $2.2 million for Q4 2023, which was down 0.00% from $2.2 million recorded in Q3 2023.
  • Aclaris Therapeutics' 5-year Liabilities from Discontinued Operations high stood at $14.5 million for Q3 2019, and its period low was $2.2 million during Q3 2021.
  • Its 3-year average for Liabilities from Discontinued Operations is $2.3 million, with a median of $2.2 million in 2023.
  • Per our database at Business Quant, Aclaris Therapeutics' Liabilities from Discontinued Operations slumped by 77.24% in 2020 and then soared by 35.17% in 2021.
  • Aclaris Therapeutics' Liabilities from Discontinued Operations (Quarterly) stood at $4.2 million in 2019, then declined by 25.16% to $3.1 million in 2020, then decreased by 29.22% to $2.2 million in 2021, then remained steady at $2.2 million in 2022, then remained steady at $2.2 million in 2023.
  • Its last three reported values are $2.2 million in Q4 2023, $2.2 million for Q3 2023, and $2.2 million during Q2 2023.